Subtype
Male Reproductive System Neoplasm
CI-CAN-00001107Explore in graph →
Non-malignant1,533 active trials27 approved drugs58 evidence items
- NCIt
- C3054
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001107Explore in graph →
Clinical trials
6,899 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04727710 | Testing the Effect of Mindfulness for Prostatectomy Outcomes(TEMPO) | terminated | N/A | 1 | University of Michigan Rogel Cancer CenterOTHER | 1 | Oct 10, 2022 | clinicaltrials |
| NCT04237584 | A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients(ESCALATE) | terminated | Phase 3 | 23 | MANA RBMOTHER | 1 | Oct 7, 2022 |
| clinicaltrials |
| NCT01174199 | Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer | terminated | Phase 1 | 13 | Roswell Park Cancer InstituteOTHER | 1 | Oct 3, 2022 | clinicaltrials |
| NCT04535908 | Hypofractionated Radiotherapy in Prostate Cancer Patients Aged 75 Years or Older. | terminated | N/A | 23 | Medical University of GrazOTHER | 1 | Oct 3, 2022 | clinicaltrials |
| NCT02766478 | Genistein Supplementation to Mitigate Cardiometabolic Dysfunction in Patients Undergoing Androgen Deprivation Therapy for Prostate Cancer(GeniPro) | terminated | Phase 2 | 10 | Emory UniversityOTHER | 1 | Sep 27, 2022 | clinicaltrials |
| NCT04279561 | Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer | terminated | Phase 1 | 9 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT02203513 | A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer | terminated | Phase 2 | 111 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2022 | clinicaltrials |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | terminated | Phase 1 | 61 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.INDUSTRY | 2 | Aug 18, 2022 | clinicaltrials |
| NCT03553732 | An Electronic Registry to Improve Adherence to Active Surveillance Monitoring at a Safety-net Hospital | terminated | — | 48 | University of California, San FranciscoOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT02419846 | Informed Decision Making Intervention in Screening for Prostate Cancer of Predominantly African American Participants in a Community Outreach Program | terminated | N/A | 319 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT03531827 | Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment | terminated | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | Jul 12, 2022 | clinicaltrials |
| NCT01681433 | OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone | terminated | Phase 2 | 72 | Costantine AlbanyOTHER | 2 | Jul 11, 2022 | clinicaltrials |
| NCT02499952 | Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors | terminated | Phase 2 | 12 | Nasser Hanna, M.D.OTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT02582749 | Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases | terminated | Phase 2 | 16 | Ajjai Alva, MDOTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT04634344 | Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC | terminated | Phase 1 | 16 | Dizal PharmaceuticalsINDUSTRY | 2 | Jul 11, 2022 | clinicaltrials |
| NCT02663908 | A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease(PRONOUNCE) | terminated | Phase 3 | 545 | Ferring PharmaceuticalsINDUSTRY | 12 | Jun 29, 2022 | clinicaltrials |
| NCT03964337 | Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer(SPARC) | terminated | Phase 2 | 3 | Duke UniversityOTHER | 1 | Jun 29, 2022 | clinicaltrials |
| NCT03290508 | Long-term Study to Evaluate and Clinical Outcomes in Patients With Favorable Intermediate Risk Localized Prostate Cancer | terminated | — | 524 | Myriad Genetic Laboratories, Inc.INDUSTRY | 1 | Jun 23, 2022 | clinicaltrials |
| NCT02837042 | Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma | terminated | Phase 2 | 6 | University of Alabama at BirminghamOTHER | 1 | Jun 21, 2022 | clinicaltrials |
| NCT02365883 | Transrectal Photoacoustic Imaging of the Prostate | terminated | — | 22 | Stanford UniversityOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT03152448 | Prospective Prolaris Value and Efficacy(P-PROVE) | terminated | — | 1,511 | Myriad Genetic Laboratories, Inc.INDUSTRY | 1 | Jun 13, 2022 | clinicaltrials |
| NCT03367819 | Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies | terminated | Phase 1 / Phase 2 | 44 | SanofiINDUSTRY | 5 | May 16, 2022 | clinicaltrials |
| NCT02913131 | Hyperpolarized C-13 Pyruvate as a Biomarker in Patients With Advanced Solid Tumor Malignancies | terminated | Phase 1 / Phase 2 | 23 | Rahul AggarwalOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT02945813 | SAKK 08/15 - PROMET - Salvage Radiotherapy +/- Metformin for Patients With Prostate Cancer After Prostatectomy | terminated | Phase 2 | 112 | Swiss Cancer InstituteOTHER | 3 | Apr 14, 2022 | clinicaltrials |
| NCT02349386 | Maintaining Suppression of Testosterone With Transdermal Estradiol Gel(MASTERS) | terminated | Phase 2 | 34 | BHR Pharma, LLCINDUSTRY | 1 | Mar 31, 2022 | clinicaltrials |
| NCT04357717 | ExoDx Prostate Evaluation in Prior Negative Prostate Biopsy Setting | terminated | — | 150 | Exosome Diagnostics, Inc.INDUSTRY | 1 | Mar 31, 2022 | clinicaltrials |
| NCT04221828 | Trial of NanoPac Focal Therapy for Prostate Cancer | terminated | Phase 2 | 1 | NanOlogy, LLCINDUSTRY | 1 | Mar 29, 2022 | clinicaltrials |
| NCT03366792 | Comparative Analysis of Transperineal Versus Transrectal Approaches for MRI-Targeted Biopsy of the Prostate for the Detection and Characterization of Prostate Cancer | terminated | N/A | 46 | NYU Langone HealthOTHER | 1 | Mar 23, 2022 | clinicaltrials |
| NCT01976962 | Functional MR-guided Stereotactic Body Radiation Therapy of Prostate Cancer | terminated | N/A | 20 | CancerCare ManitobaOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT02362451 | Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men With Stage D0 Prostate Cancer | terminated | Phase 2 | 7 | National Cancer Institute (NCI)NIH | 1 | Mar 18, 2022 | clinicaltrials |
| NCT04960956 | Glycosylation of Exosomes in Prostate and Urothelial Carcinoma | terminated | — | 13 | Indiana UniversityOTHER | 1 | Mar 14, 2022 | clinicaltrials |
| NCT04393831 | A Prospective Trial on Nerve Sparing Techniques Performed in Radical Prostatectomy | terminated | N/A | 3 | Weill Medical College of Cornell UniversityOTHER | 1 | Mar 11, 2022 | clinicaltrials |
| NCT01650285 | Cabazitaxel and Radiation For Patients With Prostate Cancer | terminated | Phase 2 | 5 | Brown UniversityOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT01650350 | Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer | terminated | Phase 2 | 7 | Brown UniversityOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT03441464 | Feasibility of the LUM Imaging System for Detection of Prostate Cancer | terminated | Phase 1 / Phase 2 | 9 | Lumicell, Inc.INDUSTRY | 1 | Feb 25, 2022 | clinicaltrials |
| NCT03630393 | Ultralow Versus Standard Pneumoperitoneum Pressure(Ultralow) | terminated | N/A | 170 | OhioHealthOTHER | 1 | Feb 18, 2022 | clinicaltrials |
| NCT00594620 | Soy Derivatives for Control of Hot Flashes in Men on Androgen Deprivation Therapy | terminated | Phase 2 | 11 | University of Kansas Medical CenterOTHER | 1 | Feb 14, 2022 | clinicaltrials |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | terminated | Phase 1 | 67 | MacroGenicsINDUSTRY | 3 | Feb 8, 2022 | clinicaltrials |
| NCT03689582 | Radiolabeled Gallium-68 (68Ga-PSMA) for PET/CT Imaging to Detect Prostate Cancer | terminated | Phase 2 | 11 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 5, 2022 | clinicaltrials |
| NCT01098331 | Implant Radiation Therapy or Surgery in Treating Patients With Prostate Cancer | terminated | N/A | 30 | University of SouthamptonOTHER | 1 | Dec 27, 2021 | clinicaltrials |
| NCT02648919 | Clinical Study of Noni Extract in Men With Very Low Risk or Low Risk Prostate Cancer | terminated | Phase 2 | 6 | University of HawaiiOTHER | 1 | Nov 26, 2021 | clinicaltrials |
| NCT02506114 | Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer | terminated | Phase 2 | 15 | Lawrence FongOTHER | 1 | Nov 24, 2021 | clinicaltrials |
| NCT02767921 | sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer | terminated | Phase 1 | 2 | University of Southern CaliforniaOTHER | 1 | Nov 24, 2021 | clinicaltrials |
| NCT03712930 | Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency | terminated | Phase 2 | 13 | BeiGeneINDUSTRY | 4 | Nov 17, 2021 | clinicaltrials |
| NCT00955929 | Pharmacological Penile Rehabilitation in the Preservation of Erectile Function Following Bilateral Nerve-Sparing Radical Prostatectomy | terminated | N/A | 76 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 10, 2021 | clinicaltrials |
| NCT03952793 | Organoids From Metastases of Prostate Cancer(OrMePro) | terminated | N/A | 1 | Centre Antoine LacassagneOTHER | 1 | Nov 1, 2021 | clinicaltrials |
| NCT03886493 | Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer | terminated | Phase 2 | 7 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 15, 2021 | clinicaltrials |
| NCT04052204 | Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 3 | PfizerINDUSTRY | 4 | Oct 14, 2021 | clinicaltrials |
| NCT02508636 | Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer | terminated | Phase 2 | 11 | University of California, San FranciscoOTHER | 1 | Oct 12, 2021 | clinicaltrials |
| NCT02565901 | Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 28 | University of WashingtonOTHER | 1 | Oct 1, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Oct 10, 2022source: clinicaltrials